SEC Form SC 13D filed by HomeTrust Bancshares Inc.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

(Amendment No. ___) to

HomeTrust Bancshares, Inc.

(Name of Issuer)

Common Stock, Par Value $.01 Per Share

(Title of Class of Securities)

437872104

(CUSIP Number)

IL Advisors, LLC C/O Bryan Cohen

2817 Mabry Road

Atlanta, Georgia 30319

(Name, Address, Telephone Number of Person Authorized to Receive Notices and Communications)

February 12, 2023

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d- 1(g), check the following box ¨.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

The title and class of equity security to which this Schedule 13D relates is the common stock, par value $.01 per share (the “Common Stock”), of HomeTrust Bancshares, Inc. (the “Issuer” or the “Company”), whose principal executive offices are located at 10 Woodfin Street, Asheville, North Carolina 28801

Infinity Trust dated December 1, 2017 (the “Trust”); and

Narasimhulu Neelagaru (“Dr. Neelagaru”). Dr. Neelagaru is the grantor and protector of the Trust.

The business address of Dr. Neelagaru is 2817 Mabry Road, Atlanta, Georgia 30319

Dr. Neelagaru: Investor

During the last five years, no Reporting Person has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

For Dr. Neelagaru: United States

On February 12, 2023, HomeTrust Bancshares, Inc. consummated its merger with Quantum Capital Corp. (“Quantum”) whereby Quantum was merged with and into the Company (the “Merger”). As a result of the merger, Infinity Trust received merger consideration of 1,153,312 shares of Common Stock (and cash) in exchange for its shares of Quantum. In addition, as a result of the merger, Dr. Neelagaru received 221,334 shares of Common Stock (and cash) in exchange for his shares of Quantum.

Each Reporting Person currently intends to hold all of the acquired securities for investment purposes.

The information contained on the cover pages to this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 is incorporated herein by reference.

(a) and (b)

* Bryan Cohen and Dr. Suleka Neelagaru, as the members of IL Advisors, LLC, the trustee of Infinity Trust , may be deemed to have control over the Trust. Within the past three years, prior to the Merger, Mr. Cohen and Dr. Suleka Neelagaru were directors of Quantum and Quantum National Bank, and Mr. Cohen was President of Quantum and Chief Executive Officer of Quantum National Bank. Since the Merger, Mr. Cohen has served as Georgia Market President of HomeTrust Bank. The grantor and initial protector of the Trust is Dr. Narasimhulu Neelagaru, who is the father of Dr. Suleka Neelagaru.

There are no contracts, arrangements, understandings or relationships (legal or otherwise) between Infinity Trust, Dr. Neelagaru and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of such securities, finder’s fees, joint ventures loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies except that as a result of the of the merger, Dr. Neelagaru is expected to join the board of the Issuer in June of 2023.

None.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 21, 2023